DecImmune gets $3.2M funding
DecImmune Therapeutics, a Massachusetts-based medical research company, received a $1 million equity investment from Astellas Venture Management, the company has announced. DecImmune also received $2.2 million in Phase II Small Business Innovation Research funding from the National Institutes of Health. Amgen Ventures and HealthCare Ventures also participated in the financing.
27 September 2010•4 mins read
